Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of December 2016, with a specific report date of December 19, 2016. The registrant is a foreign private issuer based in Rehovot, Israel, and files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to distribute a press release rather than to report financial results.
Material Changes
The primary material event disclosed is the company's decision to transfer its stock exchange listing to the NASDAQ stock market, as detailed in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the announcement of the listing transfer.
Investor Verification Checklist
- Verify the effective date and approval status of the transfer to NASDAQ.
- Confirm the new trading symbol and ticker for Evogene Ltd. on NASDAQ.
- Review the attached press release (Exhibit 99.1) for details on the rationale and timeline for the listing change.